Adicon Ends $204 Million Crown Biosciences Deal
The Hangzhou-based lab network's planned acquisition of Crown Biosciences from JSR Life Sciences was terminated after approvals were not secured in time.
Updated on Nov. 20, 2026 in Healthcare

Adicon and JSR Life Sciences have terminated the agreement under which Adicon would have acquired Crown Biosciences for $204 million. The transaction did not obtain necessary regulatory approvals within the agreed timeframe, even after the deadline was extended to Nov. 13.
Why it matters
The collapse leaves Crown Biosciences under continued ownership by JSR Life Sciences, which bought the company in 2017 for $400 million. The outcome shows how regulatory timing can derail cross-border healthcare research deals even after the parties agree on terms.
The $204 million agreement combined a $120 million up-front payment with conditional payments of $40 million and $44 million, against the $400 million JSR paid for Crown in 2017. The source does not indicate what regulatory approvals remained outstanding when the deal lapsed.
The players
Adicon
Adicon is a Hangzhou-based network of medical laboratories that held Adicon Holdings through its Miramar Lifesciences subsidiary as the planned acquirer.
JSR Life Sciences
JSR Life Sciences is the life sciences arm of Japanese materials company JSR and is the parent of Crown Biosciences.
Crown Biosciences
Crown Biosciences is a preclinical oncology research company with operations in the U.S., Europe and Asia that was the target of the terminated sale.
The details
Adicon, a Hangzhou-based network of medical laboratories, had agreed to acquire Crown Biosciences through its subsidiary Miramar Lifesciences, with Crown's shares to be transferred to that entity. The conditions precedent to closing were not satisfied within the originally anticipated timeframe, and the parties extended the deadline to Nov. 13 before deciding to terminate on Nov. 16. Crown Biosciences, which operates research facilities in the U.S., Europe and Asia and maintains about 1,000 tumor organoid models, will remain a subsidiary of JSR Life Sciences.
Timeline
2017: JSR Life Sciences bought Crown Biosciences for $400 million.
Nearly a year before November 2026: Adicon agreed to pay $120 million up front.
Nov. 13, 2026: The extended deadline for the transaction passed.
Nov. 16, 2026: The parties announced termination of the agreement.
Market Landscape
The failed deal reflects a wider pattern in which cross-border acquisitions of life sciences firms by Chinese buyers encounter extended regulatory review that can outlast negotiated closing windows. It also shows how sellers such as JSR Life Sciences may keep assets they had planned to divest when approvals stall.
For patients and clinicians, the outcome means Crown Biosciences keeps its current ownership and research programs without a change in direction. Readers tracking healthcare investment should note that the $40 million and $44 million conditional payments tied to the deal will not be made.
The takeaway
Cross-border healthcare deals can fail on regulatory timing alone, even when price and structure are agreed. Investors and industry watchers should treat extended closing deadlines as a signal of approval risk.
Further reading
For more on how deals like this play out across the sector, see Healthcare.
Source note: This article includes information reported by FierceBiotech - free daily biotech briefing.



